



EDAP Reports Continued and Growing Acceptance and Adoption for Ablatherm-HIFU Technology At European Association of Urology Conference

Highlights Minimally Invasive Prostate Cancer Treatment

LYON, France, Mar 25, 2009 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today its successful participation in the 24th Annual European Association of Urology (EAU) Conference, where its Ablatherm-HIFU and next generation Sonolith I-Sys were highlighted. The three-day conference is one of the world's largest urology events and attracted a record of over 12,000 attendees to Stockholm, Sweden from March 17-20, 2009.

EDAP's presence at EAU actively focused on promoting its full range of innovative, robotic, user-friendly devices, showcasing positive confirmed long-term patient outcomes. EDAP's dedicated sales, marketing and clinical team continuously advised, informed, and answered queries to increase physician awareness of the Company's minimally invasive HIFU approach for the treatment of prostate cancer.

During product demonstrations, urologists had the opportunity to assess HIFU's proven track record and patient benefits compared to more invasive treatment procedures. The EAU organization also formally invited EDAP to hold a three-day workshop at the event's Education and Progression Session, where urologists could attend dedicated e-learning training sessions for the Ablatherm-HIFU device, in an effort to increase interest and make urologists more comfortable with using the technology. In addition, the clinical superiority of the Ablatherm-HIFU and Sonolith I-Sys devices was highlighted and discussed by key long-term users during eight abstract presentations.

EDAP also used the annual major event as an opportunity to host a HIFU symposium, chaired by Professor Vincenzo Ficarra of Padua University in Italy. Key opinion leaders and long-term Ablatherm-HIFU users from France, the United Kingdom, Germany and North America presented clinical results and experiences utilizing the non-invasive application. Both current and potential Ablatherm-HIFU users also discussed current peer-to-peer literature and updated patient outcome results compiled in EDAP's @-REGISTRY database of Ablatherm-HIFU treatments.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "The EAU event, specifically our HIFU symposium of more than 200 participating urologists, was a great success for EDAP and confirmed the growing recognition of our HIFU technology. The strong response to our symposium allowed us to generate interest and gather a significant number of requests for further information on our HIFU technology. The increasing support for HIFU among urologists at the conference and our symposium, in addition to the French Association of Urology's recent publication, further validate HIFU's position as a new standard of care for the treatment of localized prostate cancer. This premier European urological event provided us with an excellent forum to demonstrate the benefits of HIFU to the urology community."

Mr. Oczachowski continued, "Ablatherm-HIFU continues to build momentum as a standard of care as both a salvage and primary care treatment for localized prostate cancer. We remain dedicated to our focus on increasing physician adoption and patient awareness of HIFU's benefits as a minimally-invasive, safe and proven alternative to other, more invasive prostate cancer treatment options."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT US clinical Study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit <http://www.edap-tms.com>, <http://www.hifu-planet.com> and <http://www.pcaresearch.com> or <http://www.urotoday.com/HIFU>.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS S.A.

EDAP TMS SA

Investor Relations / Legal Affairs

Blandine Confort

+33 4 72 15 31 72

bconfort@edap-tms.com

The Ruth Group

Investors:

R.J. Pellegrino

646-536-7009

rpellegrino@theruthgroup.com

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX